Sagar Lonial MD

PubMed

• Practical Guidance on Clinical Management of Belantamab Mafodotin-Associated Ocular Events.
  Evangelos Terpos, Suzanne Trudel, María-Victoria Mateos, Nicolás Alejandre, Kathryn Colby
  American Journal of Hematology. 2025-10-01
• Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience.
  Lorenzo Cani, Sara A Scott, Danielle Roberts, Nisha S Joseph, Craig C Hofmeister
  Haematologica. 2025-09-04
• A Cure, a Cure, My Kingdom for a Cure….
  Sagar Lonial, Shaji Kumar
  Journal of Clinical Oncology. 2025-09-01

Journal Articles

• Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma  
  Nikhil C Munshi, Larry D Anderson, Deepu Madduri, Sagar Lonial, Noopur Raje, Fabio Petrocca, Kristen Hege, The New England Journal of Medicine
• Article MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation  
  Guojing Zhang, Fadlo R Khuri, Taofeek K Owonikoko, Dan Li, Conor E Steuer, Nabil F Saba, Dong M Shin, Sagar Lonial, ScienceDirect
• A Phase I/II Dose-Escalation Study Investigating All-Oral Ixazomib-Melphalan-Prednisone Induction Followed by Single-Agent Ixazomib Maintenance in Transplant-Ineligibl...  
  Michael D Craig, Sagar Lonial, Haematologica
• Identification of Novel Mutational Drivers Reveals Oncogene Dependencies in Multiple Myeloma  
  Nikhil Munshi, Kenneth C Anderson, A Keith Stewart, Sagar Lonial, Blood
• Join now to see all

Abstracts/Posters

• Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study
  Sagar Lonial, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacy...
  Sagar Lonial, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
  Sagar Lonial, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
  Sagar Lonial, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrang...
  Sagar Lonial, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Final Analysis of a Phase 1b Study of Daratumumab in Combination with Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (RRMM)Clinically Releva...
  Sagar Lonial, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Multiple Myeloma Epigenetic Programming Prognostic of Outcome Converges with Loci Reprogrammed in Relapsed/Refractory Disease
  Sagar Lonial, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Unsupervised Clustering of DNA Copy Number Profiles Identifies a High-Risk Subtype of Hyperdiploid Multiple Myeloma: An Mmrf Commpass Analysis
  Sagar Lonial, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans
  Sagar Lonial, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Molecular Characterization of Bone Marrow and Peripheral Blood Compartments from Patients with Plasma Cell Leukemia in the Mmrf Commpass Study
  Sagar Lonial, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Addressing Current Questions and Controversies in the Management of Multiple Myeloma, Amyloidosis and Waldenstr_m Macroglobulinemia (Part 2 of a 2-Part Series) 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220) 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma. 
  2019 ASCO Annual Meeting - 6/1/2019
• First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple ... 
  2019 ASCO Annual Meeting - 6/1/2019
• Split First Dose Administration of Daratumumab for the Treatment of Patients with Multiple Myeloma (MM): Clinical Pharmacology and Population Pharmacokinetic (PK) Anal... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrang... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Analysis of Sequential Patient Samples from the Mmrf Commpass Study Identifies a High Risk Progression Phenotype 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• An Integrated Genomics Analysis Identifies Recurrent Gain- and Loss-of-Function Events and in Distinct Subtypes of Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Evaluation of All Cause of Death after High Dose Chemotherapy and Autologous Stem Cell Transplant in Hodgkin Lymphoma and Non-Hodgkin Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Development and Validation of a High Risk Multiple Myeloma Gene Expression Index from RNA Sequencing: An Mmrf Commpass Analysis 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Addressing Current Questions and Controversies in the Management of Multiple Myeloma, Waldenstrom Macroglobulinemia, and Amyloidosis (Part 2 of a 2-Part Series) 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab + lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM). 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Ninth Annual Hematology Conference: An Update on Selected ASH Topics 
  The University of Tennessee Graduate School of Medicine, Knoxville, Tennessee - 1/19/2013
• Join now to see all